CN104306389A - Lincomycin-spectinomycin compound nano-emulsion - Google Patents
Lincomycin-spectinomycin compound nano-emulsion Download PDFInfo
- Publication number
- CN104306389A CN104306389A CN201410555616.5A CN201410555616A CN104306389A CN 104306389 A CN104306389 A CN 104306389A CN 201410555616 A CN201410555616 A CN 201410555616A CN 104306389 A CN104306389 A CN 104306389A
- Authority
- CN
- China
- Prior art keywords
- parts
- spectinomycin
- lincomycin
- emulsion
- compound nanometer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960000268 spectinomycin Drugs 0.000 title claims abstract description 42
- 239000007908 nanoemulsion Substances 0.000 title abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- POUMFISTNHIPTI-BOMBIWCESA-N hydron;(2s,4r)-n-[(1r,2r)-2-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methylsulfanyloxan-2-yl]propyl]-1-methyl-4-propylpyrrolidine-2-carboxamide;chloride Chemical compound Cl.CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 POUMFISTNHIPTI-BOMBIWCESA-N 0.000 claims abstract description 23
- 229960001595 lincomycin hydrochloride Drugs 0.000 claims abstract description 23
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 claims abstract description 18
- 239000004094 surface-active agent Substances 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 239000000839 emulsion Substances 0.000 claims description 30
- 239000004064 cosurfactant Substances 0.000 claims description 14
- 239000003921 oil Substances 0.000 claims description 13
- 235000019198 oils Nutrition 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 claims description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims description 2
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005642 Oleic acid Substances 0.000 claims description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 2
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229940117916 cinnamic aldehyde Drugs 0.000 claims description 2
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 239000004519 grease Substances 0.000 claims description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- -1 polyoxyethylene Polymers 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract description 2
- 230000035699 permeability Effects 0.000 abstract description 2
- 230000003307 reticuloendothelial effect Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000036470 plasma concentration Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 21
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 10
- 239000007864 aqueous solution Substances 0.000 description 9
- 229960005287 lincomycin Drugs 0.000 description 9
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000007674 genetic toxicity Effects 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000012430 stability testing Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010007882 Cellulitis Diseases 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 201000008235 Mycoplasma pneumoniae pneumonia Diseases 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010035724 Pneumonia mycoplasmal Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010074268 Reproductive toxicity Diseases 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000007688 immunotoxicity Effects 0.000 description 1
- 231100000386 immunotoxicity Toxicity 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108010091047 neurofilament protein H Proteins 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 231100000191 repeated dose toxicity Toxicity 0.000 description 1
- 230000007696 reproductive toxicity Effects 0.000 description 1
- 231100000372 reproductive toxicity Toxicity 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 229960000887 spectinomycin hydrochloride Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000003439 teratogenic agent Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides lincomycin-spectinomycin compound nano-emulsion, and belongs to the technical field of pharmacy. The compound nano-emulsion is prepared from the following components in parts by weight: 1-20 parts of lincomycin hydrochloride, 1-25 parts of spectinomycin, 15-40 parts of surfactant, 1-25 parts of co-surfactant, 1-16 parts of oil and 18-75 parts of water. The compound nano-emulsion is a novel preparation which is combined with characteristics of lincomycin hydrochloride and lincomycin hydrochloride, and has the advantages of uniform grain diameter distribution, good fluidity, high stability, good permeability and good bioavailability; the compound nano-emulsion can be quickly phagocytosed by reticuloendothelial cells after being taken orally, drugs can quickly take effects, and constant plasma concentration and pharmacological effect can be maintained, the bioavailability can be improved, drug effect can be enhanced, and using amount and taking times of the medicine can be reduced.
Description
Technical field
The invention belongs to pharmaceutical technology sectors, be specifically related to a kind of lincomycin-spectinomycin compound nanometer emulsion.
Background technology
Lincomycin hydrochloride (Lincomycin Hydrochloride) is white crystalline powder, and soluble in water or methanol, is slightly soluble in ethanol.Lincomycin hydrochloride is narrow-spectrum antibiotic, and its effect is similar to erythromycin, has better effect, have efficiently especially to anaerobic bacteria, S. aureus L-forms and streptococcus pneumoniae gram positive coccus.Lincomycin hydrochloride can the synthesis of anti-bacteria cell protein, is clinically mainly used in responsive microbial various infection, as pneumonia, meningitis, endocarditis, cellulitis, tonsillitis, erysipelas, furuncle and urinary system infection etc.Because this product can enter in osseous tissue, there is special affinity with bone, therefore be specially adapted to lonely microbial infection and S. aureus L-forms osteomyelitis.
Spectinomycin is a kind of aminocyclitol antibiotic be combined into by neutral sugar and aminocyclitol one glycosidic bond, mainly has height antibacterial activity to Diplococcus gonorrhoeae, also has good antibacterial activity to the Diplococcus gonorrhoeae producing beta lactamase; To many enterobacteriaceae lactobacteriaceae tool moderate antibacterial activities.Pu Luofeideng bacterium and Pseudomonas aeruginosa are usually to this product drug resistance; Often still responsive to streptomycin, gentamycin, tobramycin etc. to the bacterial strain of this product drug resistance.These product have good action to ureaplasma urealyticum, to chlamydia trachomatis and treponema pallidum non-activity.The mechanism of action of these product is combined with bacterial ribosome 30S subunit, the synthesis of anti-bacteria protein.Veterinary pharmacologically, spectinomycin is used for preventing and treating colibacillosis, fowl cholera, fowl salmonellosis.Combine with lincomycin, can be used for preventing the acute and chronic respiratory tract disease etc. that piglet diarrhea, the mycoplasmal pneumonia of pig and Frustrate blood and mycoplasma cause.
At present, on market, more existing lincomycins and spectinomycin combined dosage form, as soluble powder, water type injection, oil suspension injection etc., be injecting drug use.This is because existing dosage form is normally used is the hydrochloride form of spectinomycin, and spectinomycin hydrochloride is soluble in water, exists under the pH environment of small intestinal with the high valence ion form of high polarity, fat-soluble minimum, orally not easily to absorb.Further, spectinomycin aqueous solution is unstable, easily hydrolysis occurs thus loses biological activity.But in practice, the treatment of a lot of disease needs medication 5-7 day more than, and injecting drug use is very inconvenient.
Summary of the invention
Object of the present invention aims to provide a kind of new compound preparation---lincomycin-spectinomycin compound nanometer emulsion.
Based on above-mentioned purpose, this invention takes following technical scheme: lincomycin-spectinomycin compound nanometer emulsion, its weight consists of: lincomycin hydrochloride 1 ~ 20 part, spectinomycin 1 ~ 25 part, 15 ~ 40 parts, surfactant, cosurfactant 1 ~ 25 part, oil 1 ~ 16 part, 18 ~ 75 parts, water.
The weight of described compound nanometer emulsion consists of: lincomycin hydrochloride 1 ~ 14 part, spectinomycin 5 ~ 15 parts, 20 ~ 35 parts, surfactant, cosurfactant 1 ~ 10 part, oil 1 ~ 12 part, 20 ~ 50 parts, water.
The weight of described compound nanometer emulsion consists of: lincomycin hydrochloride 7 parts, spectinomycin 5 ~ 15 parts, 28 parts, surfactant, cosurfactant 4 parts, oil 12 parts, 39 parts, water.
Described surfactant be in polyoxyl 40 hydrogenated castor oil, castor oil polyoxyethylene (40) ether, Tween 80 or PLURONICS F87 any one or with the mixture of span80.
Described cosurfactant is selected from ethanol, 1,2-PD, PEG400 and glycerol.
Described grease separation is from soybean oil, cinnamic aldehyde, Ethyl formate, ethyl oleate, fatty glyceride, Oleum Ricini, Oleum Brassicae campestris, linoleic acid, ethyl n-butyrate., isopropyl myristate, ethyl acetate and oleic acid.
Described oil is isopropyl myristate.
Nano-emulsion (nanoemulsion), also known as microemulsion (microemulsion), is by spontaneous transparent or semitransparent homodisperse systems formed such as water, oil, surfactant and cosurfactants.In general, nano-emulsion is divided into three types, i.e. oil-in-water type nano-emulsion (O/W), water-in-oil type nanoemulsion (W/O) and bicontinuous nano-emulsion (B.C).Nano-emulsion has the unrivaled advantage of other preparations many: 1. for isotropic transparency liquid, belongs to thermodynamically metastable fixed system, through pressure sterilizing or centrifugally can not make it layering; 2. technique is simple, and preparation process does not need special installation, can spontaneously be formed, and nano-emulsion particle diameter is generally 1 ~ 100nm; 3. viscosity is low, can reduce pain during injection; 4. there is slow release and targeting; 5. improve the dissolubility of medicine, reduce medicine enzymolysis in vivo, can be formed the protective effect of medicine and improve the absorption of gastrointestinal tract to medicine, improving the bioavailability of medicine.
Material rate is obtained according to the present invention, what prepare is oil-in-water type nano-emulsion, its preparation method can be: take spectinomycin, surfactant and cosurfactant stirred at ambient temperature in proportion even, and then instillation is dissolved with the distilled water (lincomycin hydrochloride aqueous solution) of lincomycin hydrochloride; The initial stage system dripping lincomycin hydrochloride aqueous solution can become sticky thick, and along with the increase gradually of lincomycin hydrochloride aqueous solution, system stickiness increases gradually; When the amount of aqueous solution increases to a certain degree, system becomes oil-in-water type from Water-In-Oil, and its viscosity can turn suddenly rare, namely obtains water white oil-in-water type nano-emulsion; Continue to add remaining aqueous solution, obtain lincomycin-spectinomycin compound nanometer emulsion cost.Lincomycin hydrochloride dissolves by the water that also can first take a morsel, and adds remaining water again after being added system.
Its emulsion particle diameter of the nano-emulsion that the present invention obtains is 30.1 ~ 71.8nm, and mean diameter is 53.3nm.It is directly oral that this nano-emulsion can be used as oral liquid, also can be encapsulated in capsule further or make lyophilized powder.
The present invention adds bland cosurfactant as ethanol, 1 in medicine, 2-propylene glycol, glycerol, Macrogol 200, Liquid Macrogol or PEG400, except hydrotropy effect, cosurfactant is mainly in order to the hydrophile-lipophile balance value (HLB) of adjustment form surface-active agent, oil water interfacial tension is reduced further, increases profit and the rigidity of limitans.Cosurfactant penetrates in interfacial film, promotes to form the very little film of radius of curvature, expands the newborn district area of nano-emulsion.
The present invention provides in conjunction with the characteristic of lincomycin hydrochloride and spectinomycin and is a kind ofly suitable for oral novel form, its product cut size is evenly distributed, good fluidity, stability is high, there is good permeability and bioavailability: can be engulfed by reticuloendothelial cell rapidly after oral administration, make medicine rapid-onset and maintain constant blood drug level and pharmacodynamics effect, bioavailability improves, strengthen drug effect, thus reduces consumption and the access times of medicine.
Meanwhile, the preparation method of nano-emulsion is easy, energy consumption is low, has wide marketing prospect.Gained nano-emulsion product can directly orally use, or is processed into other dosage forms further through encapsulated and lyophilized powder technology.
Accompanying drawing explanation
Fig. 1 is the transmission electron microscope photo of lincomycin in embodiment 1-spectinomycin compound nanometer emulsion;
Fig. 2 is the grain size distribution of lincomycin in embodiment 1-spectinomycin compound nanometer emulsion.
Detailed description of the invention
Below in conjunction with specific embodiment and dependence test experiment the present invention will be further described.
one) embodiment
For making description concise and to the point, provide each specific embodiment in the form of a list below.
The list of table 1 each embodiment component
The preparation method of embodiment 1-10 is: take lincomycin hydrochloride and be dissolved in distilled water and be mixed with lincomycin hydrochloride aqueous solution; Take spectinomycin, surfactant, cosurfactant, stirred at ambient temperature mix homogeneously, then slowly instill lincomycin hydrochloride aqueous solution.Along with the increase of the distillation water yield, system viscosity increases; When the amount adding distilled water makes system become oil-in-water type nano-emulsion from Water-In-Oil, system viscosity is thinning from the state of most thickness, forms water white nano-emulsion system; Add remaining lincomycin hydrochloride aqueous solution, get product.
two) test experiments
(1) granularmetric analysis
Observe the nano-emulsion product of embodiment 1-10 under transmission electron microscope, find that drop is that class is spherical, good dispersion, without adhesion.Fig. 1 is the transmission electron microscope photo of lincomycin in embodiment 1-spectinomycin compound nanometer emulsion.Utilize the nano-emulsion of Malvern Particle Size Analyzer to embodiment 1 to detect, testing result as shown in Figure 2.As can be seen from Figure 2, emulsion particle diameter is distributed between 30.1 ~ 71.8nm, and mean diameter is 53.3nm.
(2) stability analysis
The nano-emulsion product of Example 1-10 carries out high speed centrifugation test, photo-stability testing, temperature stability test etc. respectively, observe the stability of lincomycin of the present invention-spectinomycin compound nanometer emulsion, be confirmed whether that the wild effects such as layering, muddiness or crystal precipitation occur.
high speed centrifugation is tested
Sample thief loads in centrifuge tube, with centrifugal 10 min of the rotating speed of 15000 r/min.Centrifugally rear sample to be observed, find each embodiment sample still can keep after centrifugation centrifugal before clear state, there is not the phenomenons such as layering, muddiness or crystal precipitation.
photo-stability testing
Getting each embodiment sample loads in water white vial, sealing, is positioned over 10d under normal lighting conditions, observes respectively at 1d, 2d, 4d, 6d, 8d, 10d sampling.Result shows, within the 10d observation period, each embodiment sample all keeps clear state, has no the wild effects such as layering, muddiness or crystal precipitation.
temperature stability test
Get each embodiment sample, every each embodiment divides three parts, loads in water white vial, sealing.Each point of sample is positioned over respectively 4 DEG C, keeps sample in room temperature (25 DEG C) and 40 DEG C of environment and investigate 30d, observe every 5d sampling.Result shows, within the 30d observation period, lincomycin, the spectinomycin nano-emulsion of embodiment 1-10 all keep clear under three kinds of temperature conditions, have no the wild effects such as layering, muddiness or crystal precipitation.
long-term stable experiment
3 batches of nano-emulsions are sealed in Brown Glass Brown glass bottles and jars only, be placed in (25 ± 2) DEG C, relative humidity (60 ± 5) % condition lower 12 months, sample respectively at when 0,3,6,9 and 12 months, investigate character and the changes of contents of nano-emulsion, and list of references statistical analysis technique, calculate the effect duration of lincomycin-spectinomycin compound nanometer emulsion.Result of the test shows under long term test condition, and the outward appearance of lincomycin-spectinomycin compound nanometer emulsion keeps clear and bright, homogeneous always, has no the phenomenons such as layering, complexion changed, flocculation and breakdown of emulsion; Lincomycin in system and spectinomycin content extend in time and reduce gradually, and the equation of linear regression provided according to content-time changing curve, the effect duration calculating lincomycin-spectinomycin is 35.12 months (with time short person for standard).
(3) toxicity test
With commercially available sharp proceomycin for contrast agents, carry out acute toxicity test according to new drug nonphosphorylated neurofilament H method: repeated dose toxicity test, genetic toxicity test (comprising Salmonella reversion test, Micronuclei In The Mouse Bone Marrow test, the test of In vitro culture mammalian cell chromosome mutation), reproductive toxicity test (General Reproductiv e Toxicity Assessment, sensitive period to teratogenic agent toxicity test, perinatal toxicity are tested), carcinogenic test, immunotoxicity test and Local irritation study, result of the test is as follows:
This product is to Mouse Acute Toxicity experiment conclusion: contrast with commercially available sharp proceomycin, and lincomycin-spectinomycin compound nanometer emulsion does not occur measuring interior untoward reaction and death.
The Salmonella reversion test of product of the present invention, the result of the genetic toxicity test such as mouse inbred strain and testis chromosomal aberration test are feminine gender.
The result that rat 30d feeds product of the present invention shows: contrast with commercially available sharp proceomycin, within experimental period, in lincomycin of the present invention-spectinomycin compound nanometer emulsion metering, each test group of animals growth promoter is good, the indexs such as body weight, food ration, routine blood test, blood biochemistry, organ coefficient are all within normal range, and histopathologic examination is no abnormality seen also.
This product long term toxicity test conclusion: contrast with commercially available sharp proceomycin, within experimental period, in lincomycin-spectinomycin compound nanometer emulsion dosage, gastric infusion has no rat untoward reaction for three months continuously, every Index for examination is all within normal range, and its main organs of pathologic finding and target organ are showed no the toxic pathological change that this guiding drug rises.
(4) pharmacokinetics
Result of the test shows, lincomycin of the present invention-spectinomycin compound nanometer emulsion oral absorption rapidly, completely.Blood eliminates half-life (t
1/2b) be 1 ~ 2 hour, renal hypofunction person (creatinine clearance rate < 20ml/ minute) can extend to 20 ~ 35 hours.These product are mainly discharged through kidney with prototype, discharge about 100% after single administration in 48 hours in urine with prototype.
Claims (7)
1. lincomycin-spectinomycin compound nanometer emulsion, it is characterized in that, the weight of described compound nanometer emulsion consists of: lincomycin hydrochloride 1 ~ 20 part, spectinomycin 1 ~ 25 part, 15 ~ 40 parts, surfactant, cosurfactant 1 ~ 25 part, oil 1 ~ 16 part, 18 ~ 75 parts, water.
2. lincomycin-spectinomycin compound nanometer emulsion as claimed in claim 1, it is characterized in that, the weight of described compound nanometer emulsion consists of: lincomycin hydrochloride 1 ~ 14 part, spectinomycin 5 ~ 15 parts, 20 ~ 35 parts, surfactant, cosurfactant 1 ~ 10 part, oil 1 ~ 12 part, 20 ~ 50 parts, water.
3. lincomycin-spectinomycin compound nanometer emulsion as claimed in claim 2, it is characterized in that, the weight of described compound nanometer emulsion consists of: lincomycin hydrochloride 7 parts, spectinomycin 10 parts, 28 parts, surfactant, cosurfactant 4 parts, oil 12 parts, 39 parts, water.
4. lincomycin-spectinomycin the compound nanometer emulsion as described in as arbitrary in claim 1-3, it is characterized in that, described surfactant be in polyoxyl 40 hydrogenated castor oil, castor oil polyoxyethylene (40) ether, Tween 80 or PLURONICS F87 any one or with the mixture of span80.
5. lincomycin-spectinomycin the compound nanometer emulsion as described in as arbitrary in claim 1-3, it is characterized in that, described cosurfactant is selected from ethanol, 1,2-PD, PEG400 and glycerol.
6. lincomycin-spectinomycin the compound nanometer emulsion as described in as arbitrary in claim 1-3, it is characterized in that, described grease separation is from soybean oil, cinnamic aldehyde, Ethyl formate, ethyl oleate, fatty glyceride, Oleum Ricini, Oleum Brassicae campestris, linoleic acid, ethyl n-butyrate., isopropyl myristate, ethyl acetate and oleic acid.
7. lincomycin-spectinomycin the compound nanometer emulsion as described in as arbitrary in claim 6, it is characterized in that, described oil is isopropyl myristate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410555616.5A CN104306389A (en) | 2014-10-20 | 2014-10-20 | Lincomycin-spectinomycin compound nano-emulsion |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410555616.5A CN104306389A (en) | 2014-10-20 | 2014-10-20 | Lincomycin-spectinomycin compound nano-emulsion |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104306389A true CN104306389A (en) | 2015-01-28 |
Family
ID=52361800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410555616.5A Pending CN104306389A (en) | 2014-10-20 | 2014-10-20 | Lincomycin-spectinomycin compound nano-emulsion |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104306389A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108670951A (en) * | 2018-07-05 | 2018-10-19 | 河南牧翔动物药业有限公司 | A kind of compound sustained-released injection of gentamicin sulphate-Lincomycin Hydrochloride for animals and preparation method thereof |
CN111388498A (en) * | 2020-03-23 | 2020-07-10 | 山东迅达康兽药有限公司 | Spectinolincomycin hydrochloride soluble powder capable of being mutually dissolved with oil seedlings after being dissolved in water and preparation method thereof |
CN112006985A (en) * | 2020-07-30 | 2020-12-01 | 瑞普(天津)生物药业有限公司 | Powder injection diluent and preparation method and application thereof |
CN114748495A (en) * | 2022-05-18 | 2022-07-15 | 广东温氏大华农生物科技有限公司 | Oil-water-soluble veterinary linke grand scale compound preparation and preparation method and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102048748A (en) * | 2010-12-27 | 2011-05-11 | 华南农业大学 | Lincomycin and spectinomycin compound oil suspension injection and preparation method and application thereof |
CN102641282A (en) * | 2012-03-07 | 2012-08-22 | 西北农林科技大学 | Compound erythromycin ethylsuccinate nano emulsion antibacterial agent and preparation method thereof |
CN102973582A (en) * | 2012-11-07 | 2013-03-20 | 河南牧翔动物药业有限公司 | Compound florfenicol and neomycin sulfate nanoemulsion formulation and preparation method thereof |
WO2013105101A8 (en) * | 2012-01-13 | 2014-01-30 | Department Of Biotechnology | Solid lipid nanoparticles entrapping hydrophilic/ amphiphilic drug and a process for preparing the same |
CN104027408A (en) * | 2014-05-14 | 2014-09-10 | 河南牧翔动物药业有限公司 | Oil-in-water type compound apramycin nano-emulsion |
CN104027390A (en) * | 2014-05-14 | 2014-09-10 | 河南牧翔动物药业有限公司 | Oil-in-water type compound amphotericin B nano-emulsion |
-
2014
- 2014-10-20 CN CN201410555616.5A patent/CN104306389A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102048748A (en) * | 2010-12-27 | 2011-05-11 | 华南农业大学 | Lincomycin and spectinomycin compound oil suspension injection and preparation method and application thereof |
WO2013105101A8 (en) * | 2012-01-13 | 2014-01-30 | Department Of Biotechnology | Solid lipid nanoparticles entrapping hydrophilic/ amphiphilic drug and a process for preparing the same |
CN102641282A (en) * | 2012-03-07 | 2012-08-22 | 西北农林科技大学 | Compound erythromycin ethylsuccinate nano emulsion antibacterial agent and preparation method thereof |
CN102973582A (en) * | 2012-11-07 | 2013-03-20 | 河南牧翔动物药业有限公司 | Compound florfenicol and neomycin sulfate nanoemulsion formulation and preparation method thereof |
CN104027408A (en) * | 2014-05-14 | 2014-09-10 | 河南牧翔动物药业有限公司 | Oil-in-water type compound apramycin nano-emulsion |
CN104027390A (en) * | 2014-05-14 | 2014-09-10 | 河南牧翔动物药业有限公司 | Oil-in-water type compound amphotericin B nano-emulsion |
Non-Patent Citations (1)
Title |
---|
傅超美 等: "《中药药剂学》", 31 August 2014, 中国医药科技出版社 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108670951A (en) * | 2018-07-05 | 2018-10-19 | 河南牧翔动物药业有限公司 | A kind of compound sustained-released injection of gentamicin sulphate-Lincomycin Hydrochloride for animals and preparation method thereof |
CN111388498A (en) * | 2020-03-23 | 2020-07-10 | 山东迅达康兽药有限公司 | Spectinolincomycin hydrochloride soluble powder capable of being mutually dissolved with oil seedlings after being dissolved in water and preparation method thereof |
CN112006985A (en) * | 2020-07-30 | 2020-12-01 | 瑞普(天津)生物药业有限公司 | Powder injection diluent and preparation method and application thereof |
CN114748495A (en) * | 2022-05-18 | 2022-07-15 | 广东温氏大华农生物科技有限公司 | Oil-water-soluble veterinary linke grand scale compound preparation and preparation method and application thereof |
CN114748495B (en) * | 2022-05-18 | 2023-02-03 | 广东温氏大华农生物科技有限公司 | Oil-water double-soluble veterinary linke grand compound preparation and preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gao et al. | Preparation and characterization of Pluronic/TPGS mixed micelles for solubilization of camptothecin | |
Attama et al. | Formulation and in vitro evaluation of a PEGylated microscopic lipospheres delivery system for ceftriaxone sodium | |
Dou et al. | Self-nanoemulsifying drug delivery system of bruceine D: a new approach for anti-ulcerative colitis | |
CN102988291B (en) | Flurbiprofen axetil fat emulsion injection composition and preparation method thereof | |
Urimi et al. | Formulation development and upscaling of lipid nanocapsules as a drug delivery system for a novel cyclic GMP analogue intended for retinal drug delivery | |
CN101019833A (en) | Oil-in-oil nonaqueous microemulsion used as medicine carrier and its medicine prepn | |
CN109310626A (en) | Use of Gram-negative species in the treatment of atopic dermatitis | |
CN104306389A (en) | Lincomycin-spectinomycin compound nano-emulsion | |
Sapino et al. | Thermosensitive nanocomposite hydrogels for intravitreal delivery of cefuroxime | |
WO2006079288A1 (en) | Use of human lysozyme for preparing cosmetics against acne | |
CN104352566A (en) | Oil-in-water compound chlortetracycline nanoemulsion | |
Lu et al. | Characterization and evaluation of an oral microemulsion containing the antitumor diterpenoid compound ent-11alpha-hydroxy-15-oxo-kaur-16-en-19-oic-acid | |
CN102228432A (en) | Ofloxacin nanoemulsion antibacterial medicine and preparation method thereof | |
CN1931131A (en) | Oil-in-water type nanometer peonol emulsion oral liquid and its prepn process | |
CN104274826B (en) | A kind of oil-in-water type compound colistin nano-emulsion | |
Boddu et al. | Development and characterization of a ricinoleic acid poloxamer gel system for transdermal eyelid delivery | |
CN104027408B (en) | Oil-in-water type compound apramycin nano-emulsion | |
Gostyńska et al. | Improving the safety of clinical management of COVID-19 patients receiving aminoglycosides and parenteral nutrition: Y-site compatibility studies | |
CN104027390A (en) | Oil-in-water type compound amphotericin B nano-emulsion | |
Kenechukwu et al. | Investigation of novel solid lipid microparticles based on homolipids from Bos indicus for the delivery of gentamicin | |
RU2229286C2 (en) | Ibuprofen ointment prepared on polyethylene oxide base and eliciting anti-inflammatory effect | |
CN115501230B (en) | Rifamycin-quinozinone coupling molecule ointment and preparation method thereof | |
CN104367989A (en) | Oil-in-water type neomycin sulfate nosiheptide nanoemulsion antimicrobial medicine | |
CN102895253B (en) | Medicine composition for treating acnes as well as preparation method and application thereof | |
CN104367636A (en) | Oil-in-water type compound ceftriaxone nanoemulsion antimicrobial medicine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150128 |